序贯化疗联合埃克替尼作为晚期表皮生长因子受体突变型非小细胞肺癌的一线治疗方案
Sequential chemotherapy and icotinib as first-line treatment for advanced epidermal growth factor receptor-mutated non-small cell lung cancer.
作者信息
Sun Sheng-Jie, Han Jin-Di, Liu Wei, Wu Zhi-Yong, Zhao Xiao, Yan Xiang, Jiao Shun-Chang, Fang Jian
机构信息
Department of Medical Oncology, The Fifth Medical Center of General Hospital of Chinese People's Liberation Army, Beijing 100039, China.
Department of Internal Oncology of Chest, Beijing Cancer Hospital, Beijing 100142, China.
出版信息
World J Clin Cases. 2022 Jun 26;10(18):6069-6081. doi: 10.12998/wjcc.v10.i18.6069.
BACKGROUND
Icotinib could have potential effect and tolerability when used sequentially with chemotherapy for advanced epidermal growth factor receptor ()-mutated non-small cell lung cancer (NSCLC).
AIM
To evaluate the efficacy and safety of chemotherapy followed by icotinib maintenance therapy as first-line treatment for advanced -mutated NSCLC.
METHODS
This multicenter, open-label, pilot randomized controlled trial enrolled 68 -mutated stage IIIB/IV NSCLC patients randomized 2:3 to the icotinib alone and chemotherapy + icotinib groups.
RESULTS
The median progression-free survival in the icotinib alone and chemotherapy + icotinib groups was 8.0 mo (95%CI: 3.84-11.63) and 13.4 mo (95%CI: 10.18-16.33), respectively ( = 0.0249). No significant differences were found in the curative effect when considering different cycles of chemotherapy or chemotherapy regimen (all > 0.05).
CONCLUSION
A sequential combination of chemotherapy and EGFR-tyrosine kinase inhibitor is feasible for stage IV -mutated NSCLC patients.
背景
对于晚期表皮生长因子受体（EGFR）突变的非小细胞肺癌（NSCLC），埃克替尼与化疗序贯使用可能具有潜在疗效和耐受性。
目的
评估化疗后使用埃克替尼维持治疗作为晚期EGFR突变NSCLC一线治疗的疗效和安全性。
方法
这项多中心、开放标签的前瞻性随机对照试验纳入了68例EGFR突变的IIIB/IV期NSCLC患者，按2:3随机分为单纯埃克替尼组和化疗+埃克替尼组。
结果
单纯埃克替尼组和化疗+埃克替尼组的中位无进展生存期分别为8.0个月（95%CI：3.84-11.63）和13.4个月（95%CI：10.18-16.33）（P = 0.0249）。考虑不同化疗周期或化疗方案时，疗效无显著差异（均P>0.05）。
结论
化疗与EGFR酪氨酸激酶抑制剂序贯联合治疗IV期EGFR突变NSCLC患者是可行的。
Zotero 插件